相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'
A. O. Pisco et al.
BRITISH JOURNAL OF CANCER (2015)
Causal analysis approaches in Ingenuity Pathway Analysis
Andreas Kraemer et al.
BIOINFORMATICS (2014)
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance
Gladys Morrison et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Making Sense of Large-Scale Kinase Inhibitor Bioactivity Data Sets: A Comparative and Integrative Analysis
Jing Tang et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2014)
The solute carrier SLC35F2 enables YM155-mediated DNA damage toxicity
Georg E. Winter et al.
NATURE CHEMICAL BIOLOGY (2014)
A unique inhibitor binding site in ERK1/2 is associated with slow binding kinetics
Apirat Chaikuad et al.
NATURE CHEMICAL BIOLOGY (2014)
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies
Bhagwan Yadav et al.
SCIENTIFIC REPORTS (2014)
VAV3 mediates resistance to breast cancer endocrine therapy
Helena Aguilar et al.
BREAST CANCER RESEARCH (2014)
S6K1 inhibition enhances tamoxifen-induced cell death in MCF-7 cells through translational inhibition of Mcl-1 and survivin
Sung-Eun Hong et al.
CELL BIOLOGY AND TOXICOLOGY (2013)
Molecular Mechanisms of Selective Estrogen Receptor Modulator Activity in Human Breast Cancer Cells: Identification of Novel Nuclear Cofactors of Antiestrogen-ERα Complexes by Interaction Proteomics
Francesca Cirillo et al.
JOURNAL OF PROTEOME RESEARCH (2013)
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
Weiyi Toy et al.
NATURE GENETICS (2013)
Activating ESR1 mutations in hormone-resistant metastatic breast cancer
Dan R. Robinson et al.
NATURE GENETICS (2013)
Non-Darwinian dynamics in therapy-induced cancer drug resistance
Angela Oliveira Pisco et al.
NATURE COMMUNICATIONS (2013)
Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia
Tea Pemovska et al.
CANCER DISCOVERY (2013)
Tamoxifen Resistance in Breast Cancer
Minsun Chang
BIOMOLECULES & THERAPEUTICS (2012)
KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer
Muralidharan Anbalagan et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3
Pablo Cingolani et al.
FLY (2012)
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Daniel C. Koboldt et al.
GENOME RESEARCH (2012)
Detecting false-positive signals in exome sequencing
Karin V. Fuentes Fajardo et al.
HUMAN MUTATION (2012)
The role of estrogen receptor alpha in mediating chemoresistance in breast cancer cells
Zhinong Jiang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2012)
Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen
Ana M. Mendes-Pereira et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Systematic Analysis of MicroRNAs Targeting the Androgen Receptor in Prostate Cancer Cells
Paivi Ostling et al.
CANCER RESEARCH (2011)
Loss of Rho GDIα and Resistance to Tamoxifen via Effects on Estrogen Receptor α
Ines Barone et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2011)
Comparison of solution-based exome capture methods for next generation sequencing
Anna-Maija Sulonen et al.
GENOME BIOLOGY (2011)
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
Craig H. Mermel et al.
GENOME BIOLOGY (2011)
Oncogenic HER2δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors
Diana M. Cittelly et al.
CARCINOGENESIS (2010)
Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance
Alexandra F. Leary et al.
CLINICAL CANCER RESEARCH (2010)
Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response
Ton van Agthoven et al.
ENDOCRINE-RELATED CANCER (2010)
Inhibition of angiogenesis by quercetin in tamoxifen-resistant breast cancer cells
Soo Jin Oh et al.
FOOD AND CHEMICAL TOXICOLOGY (2010)
Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways
Sandra E. Ghayad et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Estrogen Receptor Regulates E2F1 Expression to Mediate Tamoxifen Resistance
Maggie C. Louie et al.
MOLECULAR CANCER RESEARCH (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
Establishment of an in vitro estrogen-dependent mouse mammary tumor model: a new tool to understand estrogen responsiveness and development of tamoxifen resistance in the context of stromal-epithelial interactions
Osvaldo Pontiggia et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Biological determinants of endocrine resistance in breast cancer
Elizabeth A. Musgrove et al.
NATURE REVIEWS CANCER (2009)
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts
Chad J. Creighton et al.
CANCER RESEARCH (2008)
Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma
Rameen Beroukhim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy
Grazia Arpino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Enhanced NFκB and AP-I transcriptional activity associated with antiestrogen resistant breast cancer
Yamei Zhou et al.
BMC CANCER (2007)
Bad expression predicts outcome in patients treated with tamoxifen
Elizabeth Cannings et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Functional screen for genes responsible for tamoxifen resistance in human breast cancer cells
Danielle Meijer et al.
MOLECULAR CANCER RESEARCH (2006)
Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: A mechanism of tamoxifen resistance
Yukun Cui et al.
CANCER RESEARCH (2006)
Association between Pak1 expression and subcellular localization and tamoxifen resistance in breast cancer patients
Caroline Holm et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Regulation of survivin by ErbB2 signaling: Therapeutic implications for ErbB2-overexpressing breast cancers
WL Xia et al.
CANCER RESEARCH (2006)
Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: A supporting role to the epidermal growth factor receptor
JM Knowlden et al.
ENDOCRINOLOGY (2005)
Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 40H-tamoxifen
AR Günthert et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments
R Breitling et al.
FEBS LETTERS (2004)
Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity
LA DeGraffenried et al.
CLINICAL CANCER RESEARCH (2004)
A cytoplasmic substrate of mitogen-activated protein kinase is responsible for estrogen receptor-α down-regulation in breast cancer cells:: The role of nuclear factor-κB
JN Holloway et al.
MOLECULAR ENDOCRINOLOGY (2004)
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer
CK Osborne et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling
G Reid et al.
MOLECULAR CELL (2003)
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells
JM Knowlden et al.
ENDOCRINOLOGY (2003)
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro
JMW Gee et al.
ENDOCRINOLOGY (2003)
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α -: A new model for anti-estrogen resistance
RA Campbell et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Development and characterization of a tamoxifen resistant breast carcinoma xenograft
H Naundorf et al.
BRITISH JOURNAL OF CANCER (2000)
分享论文
